1.Innovation and transcendence: advancement of foreign medical humanities education and its enlightenment on China
Chinese Journal of Medical Education Research 2013;(5):444-448
Through decades of innovation and transcendence,foreign medical universities consistently promoted integration of medicine and humanities and carried out curriculum and teaching reform.Both the ideas and measures are advanced and worthy study.Currently,the development of medical humanities education in China is confronted with difficulties.Medical students need to promote their humanistic quality urgently.The study explored the effective measures to innovate and transcend by analyzing the advancement of foreign medical humanities education and problems of medical humanities education in China.
2.Construction of autonomous-interactive mode about how to cultivate the values of medical stu-dents in the age of new media
Chinese Journal of Medical Education Research 2015;(5):534-537
Currently, the widespread use of new media challenges ideological and political education among the medical students. The study explores the effects on medical students' values by new media on the basis of analyzing its characteristics, including communication space, information, subject and route. In addition, the study analyzes the mode's theoretical construction and practical op-eration from these aspects:the mode's connotation, operation mechanism, the characteristics and prac-tical application.
3.Efficacy of insulin pump therapy of colorectal cancer complicated with type 2 diabetes mellitus in peri-operation period
Leilei WANG ; Sui ZHU ; Xiaoai ZHOU ; Yanwen NIU
China Modern Doctor 2014;(25):122-124,127
Objective To observe the clinical efficacy of control blood glucose by using CSII for the people who suf-fers?from colorectal cancer complicated with type 2 diabetes mellitus in peri-operation period. Methods Sixty patients who sufferred from colorectal cancer complicated with type 2 diabetes mellitus were selected and were randomly divid-ed into treatment group(30 cases) and control group(30 cases). The treatment group was treated with CSII (CSII group), while the control group was treated with conventional subcutaneous injection (MSII group). The blood glucose level be-fore and after treatment, blood glucose time required to reach the target, the incidence of hypoglycemia, insulin dosage, preoperative preparation time, time of hospitalization,the incidence of wound healing, and infection were detected. Re-sults Blood glucose levels of two groups decreased significantly after treatment, which reached effect satisfaction. The time of blood glucose control, the rate of hypoglycemia, insulin dosage, preoperative preparation time, hospitalization time,wound healing and infection rate of group CSII were lower than those of MSII group. Conclusion Efficacy and safety in peri-operative time of CSII in colorectal cancer operation with type 2 diabetes mellitus is superior to that of MSII.
4.Cost-effectiveness analysis of nucleic acid screening for hepatitis B and C in hospitalized patients in China
Shu SU ; Qi ZHANG ; Peng WANG ; Rong GUI ; Chunhong DU ; Xiying LI ; Xianping LYU ; Rong XIA ; Fenghua LIU ; Li QIN ; Jiameng NIU ; Lili XING ; Leilei ZHANG ; Jinqi MA ; Junhua HU ; Yuan ZHANG ; Juan CAI ; Huifang JIN ; Jun ZHANG ; Rongyi CAO ; Jiwu GONG ; Jiangcun YANG
Chinese Journal of Laboratory Medicine 2023;46(1):38-44
Objective:To compare the cost-effectiveness of hospitalized Chinese patients undergoing nucleic acid screening strategies for hepatitis B and hepatitis C, immunological screening strategy, and no screening strategy under different willingness to pay (WTP). The results might aid to decision-making for the optimal strategy.Methods:In this study, nucleic acid screening, immunological screening and no screening were used as screening strategies, and China′s GDP in 2021 (80 976 yuan) was used as the threshold of WTP to construct a Markov model. After introducing parameters related to the diagnosis and treatment of hepatitis B and C in inpatients, a cohort population of 100 000 inpatients was simulated by TreeAge Pro 2021 software, the total cost, total health effects, incremental cost-effectiveness ratio and average cost-effectiveness ratio of different screening strategies were calculated, and cost-effectiveness analysis was conducted. Univariate and probabilistic sensitivity analysis were used to assess the impact of parameter uncertainty on the final results.Results:Compared with the non-screening strategy, the incremental total cost of the hepatitis B immunological screening strategy for cohort patients was 11 049 536 yuan, and the incremental cost-effectiveness ratio was 24 762 yuan/quality-adjusted life years (QALY), while the total incremental cost of nucleic acid screening was 19 208 059 yuan, and the incremental cost-effectiveness ratio was 29 873 yuan/QALY; the incremental cost-effectiveness ratio of nucleic acid screening and immunological screening was 45 834 yuan/QALY. Compared with the non-screening strategy, the incremental cost-effectiveness ratio of hepatitis C immunological screening strategy was 5 731 yuan/QALY, the incremental cost-effectiveness ratio of nucleic acid screening strategy was 8 722 yuan/QALY, the incremental cost-effectiveness ratio of nucleic acid screening and immunological screening was 45 591 yuan/QALY. The results of probabilistic sensitivity analysis showed that when the cost of nucleic acid testing exceeded 214.53 yuan, it was not cost-effective to perform hepatitis B nucleic acid screening under the WTP as 1 fold GDP. When the cost of nucleic acid testing exceeded 132.18 yuan, it was not cost-effective to conduct hepatitis C screening under the WTP as 1 fold GDP.Conclusions:Nucleic acid screening strategy can achieve more cost-effectiveness and is worthy of vigorous promotion. Compared with no screening, both the nucleic acid and immunological screening strategies are cost-effective, and hepatitis nucleic acid screening is the optimal strategy for hospitalized patients.
5. Mechanism of DCLK1 transcriptional regulation in HCC
Xianchuang WU ; Yuxin LIU ; Leilei ZHANG ; Xianchuang WU ; Yuji NIU ; Jinjin HE ; Hui QIAO ; Jinjin HE ; Hui QIAO
Chinese Journal of Clinical Pharmacology and Therapeutics 2023;28(11):1241-1246
AIM: To investigate the molecular mechanism through which DKK1 is transcriptionally regulated in HCC (hepatocellular carcinoma) cells. METHODS: Real time PCR was used to explore whether EGFR was involved in regulating DCLK1 mRNA expression in HCC cells; Western blot assay was used to examine whether EGFR-mediated the up-regulation of DCLK1 protein in HCC cells; Immunohistochemical (IHC) analyses were used to examine the protein expression of EGFR and DCLK1 in 39 human HCC tumor specimens. RESULTS: EGF promoted the expression of DCLK1 mRNA and protein in HepG2 and Huh-7 cells (P<0.05, P<0.01), while knockdown of EGFR with two specific siRNA could reverse EGF-induced the up-regulation of DCLK1 mRNA and protein (P<0.01). IHC analyses revealed that the amount of EGFR correlated significantly with that of DCLK1 (r=0.669 6). CONCLUSION: EGFR promoted DCLK1 transcription in HCC.
6.PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism.
Mingming SUN ; Leilei LI ; Yujia NIU ; Yingzhi WANG ; Qi YAN ; Fei XIE ; Yaya QIAO ; Jiaqi SONG ; Huanran SUN ; Zhen LI ; Sizhen LAI ; Hongkai CHANG ; Han ZHANG ; Jiyan WANG ; Chenxin YANG ; Huifang ZHAO ; Junzhen TAN ; Yanping LI ; Shuangping LIU ; Bin LU ; Min LIU ; Guangyao KONG ; Yujun ZHAO ; Chunze ZHANG ; Shu-Hai LIN ; Cheng LUO ; Shuai ZHANG ; Changliang SHAN
Acta Pharmaceutica Sinica B 2023;13(1):157-173
Metabolic reprogramming is a hallmark of cancer, including lung cancer. However, the exact underlying mechanism and therapeutic potential are largely unknown. Here we report that protein arginine methyltransferase 6 (PRMT6) is highly expressed in lung cancer and is required for cell metabolism, tumorigenicity, and cisplatin response of lung cancer. PRMT6 regulated the oxidative pentose phosphate pathway (PPP) flux and glycolysis pathway in human lung cancer by increasing the activity of 6-phospho-gluconate dehydrogenase (6PGD) and α-enolase (ENO1). Furthermore, PRMT6 methylated R324 of 6PGD to enhancing its activity; while methylation at R9 and R372 of ENO1 promotes formation of active ENO1 dimers and 2-phosphoglycerate (2-PG) binding to ENO1, respectively. Lastly, targeting PRMT6 blocked the oxidative PPP flux, glycolysis pathway, and tumor growth, as well as enhanced the anti-tumor effects of cisplatin in lung cancer. Together, this study demonstrates that PRMT6 acts as a post-translational modification (PTM) regulator of glucose metabolism, which leads to the pathogenesis of lung cancer. It was proven that the PRMT6-6PGD/ENO1 regulatory axis is an important determinant of carcinogenesis and may become a promising cancer therapeutic strategy.